These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34848716)

  • 1. Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
    Valldeoriola F; Catalán MJ; Escamilla-Sevilla F; Freire E; Olivares J; Cubo E; García DS; Calopa M; Martínez-Martín P; Parra JC; Arroyo G; Arbelo JM
    NPJ Parkinsons Dis; 2021 Nov; 7(1):108. PubMed ID: 34848716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study.
    Chung SJ; Calopa M; Ceravolo MG; Tambasco N; Antonini A; Chaudhuri KR; Robieson WZ; Sánchez-Soliño O; Zadikoff C; Jin M; Barbato LM
    Parkinsons Dis; 2022; 2022():1216975. PubMed ID: 36388237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland.
    Weiss D; Ebersbach G; Möller JC; Schwarz J; Arlt C; Fritz B; Sensken SC; Eggert K
    Parkinsonism Relat Disord; 2022 Oct; 103():85-91. PubMed ID: 36087571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
    Ray Chaudhuri K; Antonini A; Robieson WZ; Sanchez-Soliño O; Bergmann L; Poewe W;
    Eur J Neurol; 2019 Apr; 26(4):581-e43. PubMed ID: 30353942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.
    Standaert DG; Aldred J; Anca-Herschkovitsch M; Bourgeois P; Cubo E; Davis TL; Iansek R; Kovács N; Pontieri FE; Siddiqui MS; Simu M; Bergmann L; Kukreja P; Robieson WZ; Chaudhuri KR
    Mov Disord Clin Pract; 2021 Oct; 8(7):1061-1074. PubMed ID: 34631942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
    Tessitore A; Marano P; Modugno N; Pontieri FE; Tambasco N; Canesi M; Latorre A; Lopiano L; Sensi M; Quatrale R; Solla P; Defazio G; Melzi G; Costanzo AM; Gualberti G; di Luzio Paparatti U; Antonini A
    J Neurol; 2018 May; 265(5):1124-1137. PubMed ID: 29516169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa infusion in Parkinson's disease: Individual quality of life.
    Ehlers C; Timpka J; Odin P; Honig H
    Acta Neurol Scand; 2020 Sep; 142(3):248-254. PubMed ID: 32383152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
    Catalán MJ; Antonini A; Calopa M; Băjenaru O; de Fábregues O; Mínguez-Castellanos A; Odin P; García-Moreno JM; Pedersen SW; Pirtošek Z; Kulisevsky J
    eNeurologicalSci; 2017 Sep; 8():44-53. PubMed ID: 29260038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
    Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
    J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LCIG in treatment of non-motor symptoms in advanced Parkinson's disease: Review of literature.
    Kamel WA; Al-Hashel JY
    Brain Behav; 2020 Sep; 10(9):e01757. PubMed ID: 32677345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Freire-Alvarez E; Kurča E; Lopez Manzanares L; Pekkonen E; Spanaki C; Vanni P; Liu Y; Sánchez-Soliño O; Barbato LM
    Mov Disord; 2021 Nov; 36(11):2615-2623. PubMed ID: 34236101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.
    Antonini A; Marano P; Gusmaroli G; Modugno N; Pacchetti C; Sensi M; Melzi G; Bergmann L; Zibetti M; Lopiano L
    Neurol Sci; 2020 Oct; 41(10):2929-2937. PubMed ID: 32342325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa-carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age.
    Morgante F; Oppo V; Fabbri M; Olivola E; Sorbera C; De Micco R; Ielo GC; Colucci F; Bonvegna S; Novelli A; Modugno N; Sensi M; Zibetti M; Lopiano L; Tessitore A; Pilleri M; Cilia R; Elia AE; Eleopra R; Ricciardi L; Cossu G
    J Neurol; 2021 May; 268(5):1728-1737. PubMed ID: 33354739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Cannas A; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Costanzo AM; Gualberti G; Melzi G; di Luzio Paparatti U; Antonini A
    Neurol Sci; 2016 Nov; 37(11):1785-1792. PubMed ID: 27421834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients.
    Sücüllü Karadağ Y; Saltoğlu T; Erdoğan Küçükdağli F; Öztürk Ö; Köseoğlu HT; Altiparmak E
    Turk J Med Sci; 2021 Feb; 51(1):84-89. PubMed ID: 32718129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.